Login / Signup

Efficacy and safety of camrelizumab combined with chemotherapy in the first-line treatment of advanced gastric cancer: a single-arm, phase II study.

Wenlou LiuHongmei WangYang ZhaoYan GeJuangjuang TangMenghan CaoSilvio MatsasDaniel Adam BreadnerXiaobing QinZhengxiang Han
Published in: Journal of gastrointestinal oncology (2024)
Camrelizumab plus SOX showed promising efficacy and an acceptable safety profile as the first-line treatment for advanced gastric cancer.
Keyphrases
  • phase ii study
  • locally advanced
  • neoadjuvant chemotherapy
  • rectal cancer
  • squamous cell carcinoma
  • radiation therapy
  • stem cells
  • transcription factor
  • open label
  • clinical trial